A carregar...
DIPG-27. OPTIMIZING CLINICAL TRIAL DESIGN: PHARMACOKINETICS OF MARIZOMIB AND PANOBINOSTAT IN A NON-HUMAN PRIMATE MODEL
BACKGROUND: Pre-clinical determination of disease-specific activity, effective dosing, safety, pharmacokinetics, and CNS delivery can optimize clinical trial designs. The proteasome inhibitor, marizomib, together with the HDAC inhibitor, panobinostat, is active and synergistic in pre-clinical DIPG s...
Na minha lista:
| Publicado no: | Neuro Oncol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6477305/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz036.048 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|